These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 structure, function and potential use for NIDDM. Gefel D; Barg Y; Zimlichman R Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146 [TBL] [Abstract][Full Text] [Related]
9. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities. Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists. Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 and islet lipolysis. Sörhede Winzell M; Ahrén B Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092 [TBL] [Abstract][Full Text] [Related]
14. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus]. Camafort-Babkowski M Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622 [TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 and diabetes 2012. Monami M; Di Pasquale G; Rowzee A; Rotella CM; Mannucci E Exp Diabetes Res; 2012; 2012():768760. PubMed ID: 23431286 [No Abstract] [Full Text] [Related]
16. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Nielsen LL; Young AA; Parkes DG Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743 [TBL] [Abstract][Full Text] [Related]
17. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Flamez D; Van Breusegem A; Scrocchi LA; Quartier E; Pipeleers D; Drucker DJ; Schuit F Diabetes; 1998 Apr; 47(4):646-52. PubMed ID: 9568699 [TBL] [Abstract][Full Text] [Related]